| Samantha Lyn Beck, MD | |
|
551 N Hillside St Ste 201, Wichita, KS 67214-4923 | |
| (316) 263-0296 | |
| Not Available |
| Full Name | Samantha Lyn Beck |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 15 Years |
| Location | 551 N Hillside St Ste 201, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104054642 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 04-37195 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kansas Surgery & Recovery Center | Wichita, KS | Hospital |
| Via Christi Hospital-wichita | Wichita, KS | Hospital |
| Hospital District #6 Patterson Health Center | Anthony, KS | Hospital |
| Pratt Regional Medical Center | Pratt, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wichita Surgical Specialists Pa | 6507840634 | 52 |
News Archive
CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.
Scientists from the Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population, propose a new concept for signalome-wide analysis of changes in intracellular pathways, called OncoFinder, which allows for accurate and robust cross-platform analysis of gene expression data.
Chronic aggressive behaviour exhibited by some boys from disadvantaged families may be due to epigenetic changes during pregnancy and early childhood.
Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
› Verified 9 days ago
| Entity Name | Ascension Via Christi Hospitals Wichita Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871589333 PECOS PAC ID: 5799696944 Enrollment ID: O20031118000404 |
News Archive
CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.
Scientists from the Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population, propose a new concept for signalome-wide analysis of changes in intracellular pathways, called OncoFinder, which allows for accurate and robust cross-platform analysis of gene expression data.
Chronic aggressive behaviour exhibited by some boys from disadvantaged families may be due to epigenetic changes during pregnancy and early childhood.
Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
› Verified 9 days ago
| Entity Name | Hospital District No. 6 Of Harper County Kansas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467427674 PECOS PAC ID: 3779571906 Enrollment ID: O20040505000589 |
News Archive
CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.
Scientists from the Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population, propose a new concept for signalome-wide analysis of changes in intracellular pathways, called OncoFinder, which allows for accurate and robust cross-platform analysis of gene expression data.
Chronic aggressive behaviour exhibited by some boys from disadvantaged families may be due to epigenetic changes during pregnancy and early childhood.
Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
› Verified 9 days ago
| Entity Name | Wichita Surgical Specialists Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154302180 PECOS PAC ID: 6507840634 Enrollment ID: O20040616000735 |
News Archive
CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.
Scientists from the Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population, propose a new concept for signalome-wide analysis of changes in intracellular pathways, called OncoFinder, which allows for accurate and robust cross-platform analysis of gene expression data.
Chronic aggressive behaviour exhibited by some boys from disadvantaged families may be due to epigenetic changes during pregnancy and early childhood.
Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samantha Lyn Beck, MD 551 N Hillside St Ste 201, Wichita, KS 67214-4923 Ph: (316) 263-0296 | Samantha Lyn Beck, MD 551 N Hillside St Ste 201, Wichita, KS 67214-4923 Ph: (316) 263-0296 |
News Archive
CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.
Scientists from the Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population, propose a new concept for signalome-wide analysis of changes in intracellular pathways, called OncoFinder, which allows for accurate and robust cross-platform analysis of gene expression data.
Chronic aggressive behaviour exhibited by some boys from disadvantaged families may be due to epigenetic changes during pregnancy and early childhood.
Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
› Verified 9 days ago
Sarah Corn, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2665 | |
Bradon Bitter, Surgery Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2665 | |
David C. Grantham, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 818 N Emporia St Ste 200, Wichita, KS 67214 Phone: 316-263-0246 Fax: 316-263-9523 | |
Dr. Duane L Osborne, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 818 N Emporia St, Suite 200, Wichita, KS 67214 Phone: 316-263-0296 Fax: 316-263-9523 | |
Dr. Therese Elizabeth Cusick, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 551 N Hillside St Ste 201, Wichita, KS 67214 Phone: 316-263-0296 Fax: 316-263-9523 | |
Dr. Eric Edward Burns, DO Surgery Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2665 | |
Jason Daniel Woolard, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 9350 E 35th St N Ste 103, Wichita, KS 67226 Phone: 316-858-5000 Fax: 316-858-5003 |